We are live on ! Find out more
TRIL

Trillium Therapeutics
TRIL

Delisted

TRIL was delisted on the 16th of November, 2021.

26 hedge funds and large institutions have $23.2M invested in Trillium Therapeutics in 2017 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

479% more capital inflows, than outflows

Capital inflows: $23.5M | Capital outflows: $4.05M

100% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 5

100% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 4

38.2% more ownership

Funds ownership: 29.82% → 68.02% (+38%)

18% more funds holding

Funds holding: 22 → 26 (+4)

Holders
26
Holders Change
+4
Holders Change %
+18.18%
% of All Funds
0.65%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
8
Reduced
4
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

TRIL Hedge Fund Activity: Q2 2017 in Review

26 of the 4,024 institutional investors tracked by Wall St. Rank reported a position in Trillium Therapeutics (TRIL) for Q2 2017, worth a combined $23.2M — up 61% from $14.4M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new TRIL positions and 5 closed out — a net gain of 5 holders — while 8 added to existing stakes and 4 trimmed.

The largest buyer was NEA Management Company, opening a new position worth an estimated $5.81M. The largest seller was Franklin Resources, cutting an estimated $2.07M.

  • 26 institutional investors held Trillium Therapeutics (TRIL) as of Q2 2017, up from 22 in Q1 2017.
  • Funds reported $23.2M of Trillium Therapeutics stock for Q2 2017, up 61% quarter-over-quarter.
  • 10 funds opened new Trillium Therapeutics positions in Q2 2017 and 5 closed out, a net change of +5 holders.
  • The largest Trillium Therapeutics buyer in Q2 2017 was NEA Management Company, an estimated $5.81M added.
  • The largest Trillium Therapeutics seller in Q2 2017 was Franklin Resources, an estimated $2.07M sold.

Based on aggregated 13F filings for Q2 2017.